Table 4.

Bleeding events across all patients

Patient	Treatment group	Antifibrotic treatment	Severity	Description	Associated CVD	Time from anticoagulant/antiplatelet treatment to event (months)a	Duration of antifibrotic treatment to event (months)
1	Group D	Pirfenidone	Mild	Ear bleeding	Coronary heart disease	31.4	27.9
2	Group A	Nintedanib	Mild	Bleeding from hemorrhoids	Arterial hypertension	–	8.6
3	Group A	Nintedanib	Mild	Hemoptysis for 3 weeks	None	–	2.7
4	Group A	Nintedanib	Mild	Bleeding from hemorrhoids	None	–	10.0
5	Group A	Nintedanib	Mild	Epistaxis and hematochezia	Arterial hypertension	–	0.3
6	Group D	Nintedanib	Moderate	Adrenal hematoma	Coronary heart disease Arrhythmia—especially AFb Heart failure	80.5	0.3
7	Group A	Nintedanib	Mild	Hematuria	Arterial hypertension Arrhythmia—especially AFc	–	3.6
8	Group C	Nintedanib	Severe	Gastrointestinal hemorrhage	Arterial hypertension	11.0	9.4

AF atrial fibrillation, CVD cardiovascular disease

^aFive patients had terminated the anticoagulant/antiplatelet treatment before the bleeding event occurred

^bType of arrhythmia not specified; patient was treated with propafenone, rivaroxaban and later dabigatran

^cSpecified as ‘supraventricular tachyarrhythmia (probably supraventricular)’ by the attending physician